Group 1 - Tianyi Medical (301097) closed at 42.92 yuan on July 18, 2025, with an increase of 1.11% and a turnover rate of 6.02% [1] - The trading volume was 11,000 shares, with a total transaction amount of 47.0881 million yuan [1] - On the same day, the net inflow of main funds was 3.7363 million yuan, while the net outflow of speculative funds and retail investors was 2.8381 million yuan and 0.8982 million yuan, respectively [2][4] Group 2 - Tianyi Medical announced a change in the use of raised funds, terminating the "Comprehensive R&D Center Construction Project" of its subsidiary, Ningbo Tairis Technology Co., Ltd., and reallocating the remaining and over-raised funds to the "Thailand Production Base Construction Project" [2] - This change was approved by the shareholders' meeting on January 13, 2025, and the company has opened a special account for the raised funds at China Industrial Bank (Thailand) [2] - A five-party supervision agreement was signed to regulate the management of the raised funds, ensuring they are used solely for the "Thailand Production Base Construction Project" [3][4]

Core Viewpoint - Ningbo Tianyi Medical Instrument Co., Ltd. has announced the establishment of a special account for raised funds and signed a five-party supervision agreement for the management of these funds, shifting the focus from a previously planned project to a new project in Thailand [1][2]. Fundraising Basic Information - The company raised a total of 14736800 shares at an issuance price of RMB 52.37 per share, resulting in total fundraising of approximately RMB 772.5 million. After deducting related expenses of RMB 18.04 million, the net amount raised is RMB 694.56 million [1][2]. Changes in Fund Usage - The company has decided to terminate the original fundraising project for the "Comprehensive R&D Center Construction Project" and redirect all remaining funds to the new "Thailand Production Base Construction Project" [1][2]. Establishment of Special Fund Account - A special account for the raised funds has been established at the Industrial and Commercial Bank of China (Thailand) with the account number 5100303754, specifically for the Thailand production base project [2][3]. Five-Party Supervision Agreement - The five-party supervision agreement includes the company, its Singapore subsidiary, its Thai subsidiary, the Industrial and Commercial Bank of China (Thailand), and the sponsor, Guotai Junan Securities. This agreement aims to regulate the management of the raised funds and protect the rights of small investors [5][6]. Fund Transfer Process - The process for transferring the remaining funds involves several steps, including returning funds from the subsidiary to the company and then transferring them to newly established accounts for both RMB and USD at the Shanghai Pudong Development Bank [2][4]. Completion of Fund Management Steps - The company has completed the necessary steps for fund management, including the reduction of capital for its subsidiary and the establishment of both RMB and USD special accounts at the Shanghai Pudong Development Bank [3][4].

证券代码：301097 证券简称：天益医疗 公告编号：2025-039 宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 并签署募集资金五方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"或"公司"）于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》，同意变更募集资金用途，同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目"，并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目"；同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日，公司已完成在中国工商银行（泰国）股份有限公司募集 资金专项账户的开立及募集资金五方监管协议的签署，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开 ...

Group 1 - The A-share medical device sector experienced a short-term surge, with Baolait rising over 17% [1] - Other stocks such as Jinan Development, Yangpu Medical, Tianyi Medical, Diri Medical, Guanhao Biological, and Chunli Medical also saw increases [1] - The rise in stock prices is attributed to the Chinese government's procurement measures affecting medical devices imported from the European Union [1]

Core Viewpoint - Ningbo Tianyi Medical Instrument Co., Ltd. has announced a change in the use of raised funds, terminating the original project for the "Comprehensive R&D Center Construction Project" and reallocating the remaining funds to the new "Thailand Production Base Construction Project" [1][2]. Fundraising Basic Information - The company raised a total of RMB 771.77 million by issuing 14.7368 million shares at RMB 52.37 per share, with net proceeds amounting to RMB 694.56 million after deducting various fees [1]. - The funds were verified by Lixin Accounting Firm, which issued a verification report [1]. Fundraising Special Account and Supervision Agreement - The company has established a special fundraising account at Shanghai Pudong Development Bank, Ningbo High-tech Zone Branch, for the new project [2][3]. - The company has signed a tripartite supervision agreement with the bank and its sponsor, Guotai Junan Securities, to oversee the use of the raised funds [3][4]. Tripartite Supervision Agreement Key Points - The special accounts for RMB and USD have been established, with balances of RMB 108.29 million and USD 0 as of July 2, 2025 [4]. - The funds in these accounts are exclusively for the "Thailand Production Base Construction Project" and cannot be used for other purposes [4]. - The sponsor has the right to supervise the use of funds and can conduct on-site investigations and inquiries [5][6]. - Any withdrawal exceeding RMB 20 million within a 12-month period must be reported to the sponsor [6].

宁波天益医疗器械股份有限公司 关于开立募集资金专项账户 证券代码：301097 证券简称：天益医疗 公告编号：2025-038 并签署募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"或"公司"）于 2024 年 12 月 27 日召开第三届董事会第二十次会议、第三届监事会第十七次会议审议 通过了《关于变更募集资金用途的议案》，同意变更募集资金用途，同意终止原 计划由子公司宁波泰瑞斯科技有限公司实施的募投项目"综合研发中心建设项 目"，并将其剩余全部募集资金变更用于新项目"泰国生产基地建设项目"；同 时同意将剩余超募资金全部调整用于"泰国生产基地建设项目"。本次变更事项 已经公司于 2025 年 1 月 13 日召开的 2025 年第一次临时股东大会审议通过。 截至本公告披露日，公司已完成部分募集资金专项账户的开立及募集资金三 方监管协议的签署，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意宁波天益医疗器械股份有限公司首 次公开发行股票注册的批复》（证监许可 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2025-037 宁波天益医疗器械股份有限公司 特此公告。 宁波天益医疗器械股份有限公司董事会 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 一次性使用连续 | 国械注准 | | 2025 | 年 5 | 月 | 30 | 日至 | 供连续性肾脏替 代治疗（CRRT） 时作为血液及液 | | 1 | 性肾脏替代治疗 | 2025310111 | III | | | | | | | | | 管路 | 2 | | 2030 | 年 | 月 5 | 29 | 日 | | | | | | | | | | | | 体通道使用。 | | 2 | | | | | | | | | 用于急、慢性肾功 能衰竭患者的血 | | | | | | | | | | | 液透析、血液透析 | | | 一次性使用血液 | 国械注准 | III | 2025 | 年 5 | 月 | 30 | 日至 ...

Core Viewpoint - Ningbo Tianyi Medical Instrument Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of 5.00 RMB per 10 shares (including tax) for shareholders, with no bonus shares or capital reserve conversion [2][3][4]. Summary by Sections Profit Distribution Plan - The company will distribute cash dividends based on a total share count of 57,519,968 shares after excluding 1,427,400 shares repurchased [2][3]. - The total cash dividend to be distributed amounts to 28,759,984 RMB [3]. Dividend Calculation - The cash dividend per 10 shares is calculated as follows: [(58,947,368 - 1,427,400) / 10 * 5] / 58,947,368 * 10 = 4.878925 RMB per 10 shares [4][9]. - The reference price for ex-dividend trading will be adjusted by subtracting the cash dividend per share from the closing price on the day before the ex-dividend date [9]. Key Dates - The record date for the dividend distribution is set for May 15, 2025, and the ex-dividend date is May 16, 2025 [5][6]. Dividend Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their securities companies on the ex-dividend date [7]. - The company will bear all legal responsibilities if there are any discrepancies in the dividend distribution due to changes in shareholders' accounts during the application period [8].

证券代码：301097 证券简称：天益医疗 公告编号：2025-036 宁波天益医疗器械股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 宁波天益医疗器械股份有限公司（以下简称"公司"）2024 年年度股东会审 议并通过了《关于 2024 年度利润分配预案的议案》。根据《中华人民共和国公司 法》《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等相关规定， 本公司回购专用证券账户中的 A 股股份不参与 2024 年度权益分派。公司以现有 总股本 58,947,368 股剔除已回购股份 1,427,400 股后的总股数 57,519,968 股 为基数，每 10 股送红股 0 股，资本公积金转增股本 0 股，派发现金 5.00 元（含 税）。 本次权益分派实施后，按公司总股本折算每 10 股现金红利及除权除息参考 价计算如下：按公司总股本（含回购股份）折算的每 10 股现金分红（含税）=本 次实际现金分红总额/公司总股本*10 股=[(58,947,368-1,427,400)/10*5]元 /58,947,368 股*10 股= ...

关于宁波天益医疗器械股份有限公司 2024 年年度股东会的法律意见书 上海璟和律师事务所 致：宁波天益医疗器械股份有限公司 宁波天益医疗器械股份有限公司（以下简称"公司"）2024 年年度股东会 于 2025 年 5 月 6 日（星期二）下午 13:00 在浙江省宁波市东钱湖旅游度假区莫 枝北路 788 号宁波天益医疗器械股份有限公司会议室如期召开。上海璟和律师 事务所经公司聘请，委派徐艺嘉律师、梅彦律师列席现场会议，根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等有关法律、行政法规、部门规章、规范性 文件以及《宁波天益医疗器械股份有限公司章程》（以下简称"《公司章 程》"）、《宁波天益医疗器械股份有限公司股东大会议事规则》（以下简称 "《议事规则》"）的规定，就本次股东会的召集和召开程序、召集人及出席 会议人员的资格、会议议案、表决方式和表决程序、表决结果和会议决议等出 具本法律意见书。 在本法律意见书中，本所律师仅对本次股东会的召集和召开程序、出席会 议人员的资格、召集人资格、会议表决程序及表决结果是否符合《公司法》 《股东会规则》《公司章 ...